Monopar Therapeutics Inc. (NASDAQ: MNPR) presented new analyses from its Phase 3 FoCus trial showing ALXN1840 provided greater neurologic benefit ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE